Use of DiviTum -TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interactions assessment and intervention in HR-positive metastatic breast cancer patients
- Study HIC#:2000033797
- Last Updated:10/02/2024
The purpose of this study is to assess optimal blood levels of this medication in the blood, and to assess medical compliance and drug-drug interactions.
Contact Us
For more information about this study, including how to volunteer, contact:
Mariya Rozenblit
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Metastatic hormone positive breast cancer with first line treatment scheduled with CDK4/6 inhibitors.
Principal Investigator
- Score: 1
